Beleaguered specialty drugmaker Salix Pharmaceuticals (SLXP) popped 4% Tuesday afternoon on word that it’s exploring a possible sale of the company. Citing anonymous sources, Reuters reported that Salix hired Centerview Partners to explore its options, though it has not yet definitely decided whether to sell itself. It wouldn’t be the first time such reports surrounded the company. In August, Allergan (AGN) was reportedly in talks to buy Salix as
Fallen former IBD 50 stock Salix Pharmaceuticals (SLXP) seemed to be getting some investor credibility back Tuesday as the company said it would clear up its inventory problems earlier than expected and offered 2015 and 2016 guidance that pointed to accelerating growth. Salix stock jumped 9% in early trading in the stock market today, near 112. Last month, Salix shocked Wall Street on its Q3 earnings report by announcing the resignation of its CFO
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker’s weak Q3 results. Are its inventories accurate, and why did CFO Adam Derbyshire resign? Shares plummeted 34% to 91.47 on the stock market today, hitting their lowest levels of the year. Law firms Ryan & Maniskas and Block & Leviton each announced Friday